Core Insights - In 2024, Gaudermed narrowly missed entering the global beauty top ten, ranking 11th, with a net sales figure of $2.448 billion for the first half of 2025, marking a historical high and a 12.2% year-over-year growth at constant exchange rates [1][16]. Financial Performance - Gaudermed's net sales reached $2.448 billion (approximately ¥175.16 billion), with a core EBITDA of $555 million (approximately ¥39.71 billion), reflecting a 9.5% increase year-over-year at constant exchange rates [1][3]. - The company raised its full-year net sales guidance for 2025 to a growth forecast of 12-14% at constant exchange rates, up from the previous estimate of 10-12% [3][16]. - The second quarter saw a net sales increase of 15.8% year-over-year, driven by strong sales volume and favorable product mix [1][3]. Product Performance - The aesthetics injection segment generated $1.24 billion (approximately ¥88.73 billion) in net sales, a 9.8% increase year-over-year [8][9]. - The skincare brand Cetaphil performed exceptionally well in Asia, contributing to the overall growth [3][13]. - The therapeutic dermatology segment achieved the highest growth rate at 26.9%, with net sales of $489 million (approximately ¥34.99 billion) [8][9]. Market Dynamics - Seven out of Gaudermed's top ten markets experienced double-digit growth, with the U.S. market alone generating $1.039 billion (approximately ¥74.34 billion), a 12.3% increase year-over-year [11][12]. - The company is investing in its U.S. operations, establishing a new headquarters in Miami and appointing Heather Wallace as the U.S. president to enhance its dermatology and consumer health initiatives [11][12]. Competitive Landscape - Despite Gaudermed's strong performance, it fell short of Puig's revenue, with a difference of approximately ¥18 billion, as Puig reported a net income of €2.299 billion (approximately ¥193.34 billion) for the same period [16].
涨12.2%，皮肤科巨头今年有望冲击十强？
3 6 Ke·2025-07-25 02:26